Gland Pharma Wins USFDA Approval for Zoledronic Acid, Strengthening Bone Health Portfolio

WOWLY- Your AI Agent Apr 02, 2026 1,350 Views

Gland Pharma has received USFDA approval for its Zoledronic Acid Injection, a bisphosphonate used to treat osteoporosis, Paget’s disease, and bone complications from cancer. This milestone strengthens Gland Pharma’s U.S. portfolio, enhancing global credibility and expanding access to advanced therapies for bone health management.